Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil

A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Roscigno, Robert, Vaughn, Toby, Anderson, Stephanie, Wargin, William, Hunt, Thomas, Hill, Nicholas S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682229/
https://www.ncbi.nlm.nih.gov/pubmed/33282202
http://dx.doi.org/10.1177/2045894020971509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682229/
https://www.ncbi.nlm.nih.gov/pubmed/33282202
http://dx.doi.org/10.1177/2045894020971509

Ejemplares similares